Biohaven prepares for FDA filing in neuro disease with no approved meds

The latest stories trending on MedCity News.

Editor's Pick

Top Story Real-World Data Salvage Biohaven Drug, Paving Way for FDA Filing in Neuro Disease With No Approved Meds Biohaven's troriluzole, which initially failed a pivotal study in spinocerebellar ataxia, is now being readied for an FDA submission in this rare neurodegenerative disease. The turnabout is based on positive results from a new study that incorporated real-world evidence. Sponsored The Promise of Value-Based Care and MedTech Innovation Presented by mHub Monica Vajani, Executive Director for mHUB's MedTech Accelerator, discusses how mHUB is helping innovators transition healthcare towards value-based care.  Learn More.

Featured News

How North Carolina Made Its Hospitals Do Something About Medical Debt In exchange for federal money, hospitals would wipe out billions of dollars of patient debt and adopt new standards to shield patients from crippling bills. 3 Things To Keep In Mind About Tech Innovation In the Cardiac Space Many new tech solutions, such as wearables and algorithms, have emerged in recent years to address the country's heart disease problem. While it's easy to get excited about technology's potential to improve cardiac care, there are a few things that healthcare leaders must keep in mind, according to Dr. Sumeet Chugh, director of the Heart Institute and director of AI in medicine at Cedars-Sinai. Tackling Global Obesity: The New, Holistic Frontier for Clinical Trials To conduct meaningful research, we must be sure to view these studies through patients' eyes. The patient perspective — in all its diversity — must be embedded into clinical trials from the very start.   Navigating Economic Uncertainty in Biopharma The biopharmaceutical industry clearly isn't going anywhere, but we've been in a downward business cycle. We've learned a lot from the pandemic and have adopted novel approaches to development and this current economic challenge will also inform us. In the meantime, adopting these strategies can de-risk your development programs.

Resources

AI in Healthcare: The Next Chapter The shifting AI landscape. Learn about the emerging technologies from AI tech developers across the healthcare landscape from health tech startups to healthcare organizations, biopharma companies, and a medtech giant. Read Free eBook Now

MedCity News • PO Box 901 • New York, NY unsubscribe